INVESTIGATING SAFETY AND PRELIMINARY EFFICACY OF AFM13 PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE

Journal article

Peer reviewed

S.M. Ansell, N.L. Bartlett, R.W. Chen, A. Herrera, E. Domingo-Domenech, A. Mehta, A. Forero-Torres, R. Garcia-Sanz, P. Armand, S. Devata, …

Hematological oncology, Vol.37(S2), pp.177-178

2019-06

Metrics

6 Record Views

Title: INVESTIGATING SAFETY AND PRELIMINARY EFFICACY OF AFM13 PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE
Creators: S.M. Ansell - Mayo Clinic
N.L. Bartlett - Washington University in St. Louis
R.W. Chen - City Of Hope National Medical Center
A. Herrera - City Of Hope National Medical Center
E. Domingo-Domenech - Clinical Hematology Instituto Catalán de Oncología L'Hospitalet Barcelona Spain
A. Mehta - University of Alabama at Birmingham
A. Forero-Torres - University of Alabama at Birmingham
R. Garcia-Sanz - Hematology Hospital Universitario de Salamanca Salamanca Spain
P. Armand - Harvard University
S. Devata - University of Michigan–Ann Arbor
A. Rodriguez Izquierdo
I.S. Lossos - University of Miami
C.B. Reeder - Mayo Clinic
T. Sher - Mayo Clinic
C. Choe-Juliak - Clinical Development Affimed, Inc. New York United States
K. Prier - Heidelberg
S.E. Schwarz - Heidelberg
A. Strassz - Heidelberg
L. Alland - Clinical Development Affimed, Inc. New York United States
Publication Details: Hematological oncology, Vol.37(S2), pp.177-178
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031713353302976